Abhya Gupta

发表

Safety, pharmacokinetics, and pharmacodynamics of single doses of an oral p38 MAP kinase inhibitor (BIRB 796 BS) in healthy human males a placebo-controlled, randomised study, double blinded at each dose level

J. Madwed, C. Wood, C. Yong, 2002 .

FEV1 recovery following methacholine challenge in asthma: Variability and comparison of methods.

Dave Singh, Abhya Gupta, N. Khan, 2019, Pulmonary pharmacology & therapeutics.

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Luca Richeldi, G. Raghu, A. Nicholson, 2011, The New England journal of medicine.

Safety, pharmacokinetics and pharmacodynamics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered once daily for 7 days

J. Madwed, C. Wood, C. Yong, 2002 .

Safety and pharmacokinetics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered twice daily for 14 days to healthy volunteers

C. Wood, C. Yong, Abhya Gupta, 2002 .

COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease.

Nicola A Hanania, Jennifer G. Dy, Raúl San José Estépar, 2019, Chronic obstructive pulmonary diseases.

Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment.

I. Hall, E. Bateman, K. Tetzlaff, 2015, Pulmonary pharmacology & therapeutics.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well‐Controlled Asthma

C. Wood, Abhya Gupta, A. Fowler, 2017, Journal of clinical pharmacology.

An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP)

B. Trapnell, F. Meloni, C. Ittrich, 2022, Scientific reports.

During Human Endotoxemia Mitogen-Activated Protein Kinase Inhibitor Anti-Inflammatory Effects of a p38

S. Deventer, J. Madwed, M. Peppelenbosch, 2002 .

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1

C. Goss, I. Fajac, Abhya Gupta, 2020, ERJ Open Research.

A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma.

E. Bateman, C. Wood, Abhya Gupta, 2017, Allergy and asthma proceedings.

Efficacy and safety of BI 671800, an oral CRTH2 antagonist in controller naïve patients with poorly-controlled asthma

E. Bateman, K. Tetzlaff, Abhya Gupta, 2012 .

Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid

I. Hall, E. Bateman, S. Atiş, 2012 .

CRTH2 Antagonist, BI 671800 (BI), Reduces Nasal Symptoms And Inhibits Nasal Cytokines And Eosinophils In SAR Patients Exposed To Grass Pollen In An Environmental Challenge Chamber (ECC)

N. Krug, J. Hohlfeld, C. Wood, 2012, ATS 2012.

Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study

C. Goss, J. Davies, I. Fajac, 2021, European Respiratory Journal.

Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis

J. Sabater, Abhya Gupta, B. Jung, 2020, ERJ Open Research.

Preclinical evaluation of the ENaC inhibitor BI 1265162 for treatment of cystic fibrosis

J. Sabater, Abhya Gupta, B. Jung, 2020 .

P38 Mitogen Activated Protein Kinase Is Involved in the Downregulation of Granulocyte CXC Chemokine Receptors 1 and 2 During Human Endotoxemia

T. van der Poll, M. Peppelenbosch, S. V. van Deventer, 2004, Journal of Clinical Immunology.

Drug‐induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides

M. Rieder, J. Uetrecht, N. Shear, 1992, Clinical pharmacology and therapeutics.

UvA-DARE ( Digital Academic Repository ) In vivo signal transduction : mitogen activated protein kinases in inflammation

Jeffrey, C. Hack, Abhya Gupta, 2007 .

Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia1

T. van der Poll, J. Madwed, C. Hack, 2002, The Journal of Immunology.

FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD

D. Lynch, J. Crapo, H. Watz, 2021, BMJ Open.

p38 mitogen-activated protein kinase inhibitor during human endotoxemia Inhibition of coagulation, fibrinolysis and endothelial cell activation by a

T. van der Poll, C. Hack, M. Peppelenbosch, 2013 .

Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis.

N. Krug, J. Hohlfeld, C. Wood, 2014, The Journal of allergy and clinical immunology.

TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

D. McAuley, L. Ware, Abhya Gupta, 2023, Thorax.

Disease profile and patient outcomes in vaccinated COVID-19 patients at a tertiary care Indian hospital: An observational, real-world study

Abhya Gupta, R. Kapoor, A. Nilakantan, 2022, Medical Journal Armed Forces India.

Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children.

G. Koren, M. Carcao, R. Lau, 1998, The Pediatric infectious disease journal.

The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers.

K. Hohl, Abhya Gupta, W. Seibold, 2023, Pulmonary pharmacology & therapeutics.

Safety and Tolerability of Four Weeks' Treatment with a Bradykinin 1 Receptor Antagonist (BI 1026706) in Patients with COPD (GOLD I-III)

A. Kirsten, Abhya Gupta, T. Litzenburger, 2019, Therapy.

Regional detection of edema following segmental LPS challenge using functional MR imaging

J. Hohlfeld, K. Hohl, M. Gutberlet, 2018, Imaging.

Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.

M. Peppelenbosch, S. V. van Deventer, Abhya Gupta, 2003, Blood.

A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf

H. Watz, A. O'donnell, P. Eickholz, 2023, ERJ Open Research.

Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.

M. Peppelenbosch, S. V. van Deventer, Abhya Gupta, 2003, Blood.